Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

CVS is set to drop Zepbound as a medicine, but will continue to carry other popular weight loss drugs instead.

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

The dramatic rise of weight-loss drugs such as Ozempic and Mounjaro had upended WeightWatchers' business model ...

Ireland has long been a global pharmaceutical powerhouse, hosting more than 90 pharmaceutical companies and employing around ...

Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.

Top-Line Data Expected in the Fourth Quarter of 2025 CAMBRIDGE, Mass., July 9, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology ...

S&P 500, Microsoft Corporation, JPMorgan Chase & Co, Eli Lilly and Company. Read 's Market Analysis on Investing.com ...

Eli Lilly's drive to provide as many treatment options as possible for its weight-loss drug Zepbound has continued with the launch of new high-dose vials sold at a $150 discount to its auto ...

Riding on horseback through brush and over numerous dead turkeys, Margo Mellon spent Tuesday scanning the flood-ravaged ...